<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887328</url>
  </required_header>
  <id_info>
    <org_study_id>NTA0901</org_study_id>
    <nct_id>NCT00887328</nct_id>
  </id_info>
  <brief_title>Extending the Time for Thrombolysis in Emergency Neurological Deficits</brief_title>
  <acronym>EXTEND</acronym>
  <official_title>Extending the Time for Thrombolysis in Emergency Neurological Deficits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroscience Trials Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commonwealth Scientific and Industrial Research Organisation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Florey Institute of Neuroscience and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuroscience Trials Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis being tested in this trial is that ischaemic stroke patients selected&#xD;
      with significant penumbral mismatch (measured by MRI criteria) at 3 - 9 hours post onset of&#xD;
      stroke will have improved clinical outcomes when given intravenous tissue plasminogen&#xD;
      activator (tPA) compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 27, 2018</completion_date>
  <primary_completion_date type="Actual">August 27, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS) 0-1</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorical shift in modified Rankin Score (mRS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ≥ 8 NIHSS points or reaching ≤ 1 on this scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to any cause</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic ICH</measure>
    <time_frame>24 hours</time_frame>
    <description>Symptomatic hemorrhage defined by SITS-MOST criteria: type 2 parenchymal hematoma associated with ≥4 point increase in NIHSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reperfusion</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recanalisation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct growth</measure>
    <time_frame>24 hours</time_frame>
    <description>Difference in volumetric DWI volume between baseline and 24 hour MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent stroke</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression (Montgomery-Asberg Depression Rating Scale [MADRS])</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Stroke Impact Scale)</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>IV tPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous tissue plasminogen activator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator (Alteplase)</intervention_name>
    <description>0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour</description>
    <arm_group_label>IV tPA</arm_group_label>
    <other_name>Actilyse</other_name>
    <other_name>Activase</other_name>
    <other_name>tPA</other_name>
    <other_name>r-tPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients presenting with hemispheric acute ischaemic stroke&#xD;
&#xD;
          2. Patient, family member or legally responsible person depending on local ethics&#xD;
             requirements has given informed consent&#xD;
&#xD;
          3. Patient's age is ≥18 years&#xD;
&#xD;
          4. Treatment onset can commence within ≥ 3 - 9 hours after stroke onset according to&#xD;
             registered product information, or within 4.5 - 9 hours according to locally accepted&#xD;
             guidelines*.&#xD;
&#xD;
             (*Guidelines are currently under international review - advisory statement issued by&#xD;
             the Stroke Council, American Heart Association and American Stroke Association)&#xD;
&#xD;
          5. Patients who wake with stroke may be included if neurological and other exclusion&#xD;
             criteria are satisfied. These 'wake up' strokes are defined as having no symptoms at&#xD;
             sleep onset, but stroke symptoms on waking. The time of stroke onset is to be taken as&#xD;
             the mid-point between sleep onset (or last known to be normal) and time of waking. The&#xD;
             maximum time window for randomisation is then 9 hours from the mid-point as described.&#xD;
&#xD;
          6. NIHSS score of ≥ 4 - 26 with clinical signs of hemispheric infarction.&#xD;
&#xD;
          7. Penumbral mismatch - A &quot;hypo-perfusion to core&quot; volume ratio of greater than 1.2 and&#xD;
             an absolute difference greater than 10mL (using a MR or CT Tmax &gt; 6 second delay)&#xD;
             between perfusion lesion and MR-DWI or CT-CBF core lesion.&#xD;
&#xD;
          8. An ischaemic core lesion volume of less than or equal to 70 ml using MR-DWI or CT-CBF&#xD;
             ** Patients may be consented before or after penumbral screening depending upon local&#xD;
             practice. The entire cohort of patients consented onto the study will be followed up&#xD;
             with clinical assessments and biomarker studies regardless of eligibility for&#xD;
             randomisation to treatment based on penumbral mismatch criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intracranial haemorrhage (ICH) identified by CT or MRI&#xD;
&#xD;
          2. Rapidly improving symptoms, particularly if in the judgment of the managing clinician&#xD;
             that the improvement is likely to result in the patient having an NIHSS score of &lt; 4&#xD;
             at randomization&#xD;
&#xD;
          3. Pre-stroke MRS score of ≥ 2 (indicating previous disability)&#xD;
&#xD;
          4. Contra indication to imaging with MR with contrast agents&#xD;
&#xD;
          5. Infarct core &gt;1/3 MCA territory qualitatively&#xD;
&#xD;
          6. Participation in any investigational study in the previous 30 days&#xD;
&#xD;
          7. Any terminal illness such that patient would not be expected to survive more than 1&#xD;
             year&#xD;
&#xD;
          8. Any condition that could impose hazards to the patient if study therapy is initiated&#xD;
             or affect the participation of the patient in the study (this applies to patients with&#xD;
             severe microangiopathy such as haemolytic uremic syndrome or thrombotic&#xD;
             thrombocytopenic purpura). The judgment is left to the discretion of the Investigator.&#xD;
&#xD;
          9. Pregnant women (clinically evident)&#xD;
&#xD;
         10. Previous stroke within last three months&#xD;
&#xD;
         11. Recent past history or clinical presentation of ICH, subarachnoid haemorrhage (SAH),&#xD;
             arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm. At the discretion of&#xD;
             each Investigator.&#xD;
&#xD;
         12. Current use of oral anticoagulants or a prolonged prothrombin time (INR &gt; 1.7) if the&#xD;
             patient is on warfarin&#xD;
&#xD;
         13. Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hours and&#xD;
             an activated prolonged partial thromboplastin time exceeding the upper limit of the&#xD;
             local laboratory normal range.&#xD;
&#xD;
         14. Use of glycoprotein IIb - IIIa inhibitors within the past 72 hours. Use of single or&#xD;
             dual agent oral platelet inhibitors (clopidogrel and/or low-dose aspirin) prior to&#xD;
             study entry is permitted.&#xD;
&#xD;
         15. Clinically significant hypoglycaemia.&#xD;
&#xD;
         16. Uncontrolled hypertension defined by a blood pressure &gt; 185 mmHg systolic or &gt;110 mmHg&#xD;
             diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring&#xD;
             aggressive treatment to reduce the blood pressure to within these limits. The&#xD;
             definition of &quot;aggressive treatment&quot; is left to the discretion of the responsible&#xD;
             Investigator.&#xD;
&#xD;
         17. Hereditary or acquired haemorrhagic diathesis&#xD;
&#xD;
         18. Gastrointestinal or urinary bleeding within the preceding 21 days&#xD;
&#xD;
         19. Major surgery within the preceding 14 days which poses risk in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
         20. Exposure to a thrombolytic agent within the previous 72 hours&#xD;
&#xD;
         21. Clinically deemed eligible for Endovascular Clot Retrieval (ECR) treatment by the&#xD;
             treating team&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Donnan, MD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Florey Institute of Neuroscence and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Davis, MD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epworth Healthcare</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>ischemic penumbra</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>diffusion imaging</keyword>
  <keyword>DWI</keyword>
  <keyword>perfusion imaging</keyword>
  <keyword>PWI</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>alteplase</keyword>
  <keyword>tPA</keyword>
  <keyword>EPITHET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

